Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.58 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.58 |
| ▸ | KCNT1 | Q5JUK3 | 2/20 | 0.45 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18077933 | 1.00 | CD274 (0.58) | CD274VSIRKCNT1PDCD1LG2PTPN1 | |
| SCHEMBL19867031 | 0.88 | VSIR (0.63) | CD274VSIRPDCD1LG2PDCD1LMNA | |
| SCHEMBL18077945 | 0.88 | VSIR (0.63) | CD274VSIRPDCD1LG2PDCD1LMNA | |
| SCHEMBL19450457 | 0.88 | VSIR (0.63) | CD274VSIRPDCD1LG2PDCD1LMNA | |
| SCHEMBL19981254 | 0.88 | KCNT1 (0.47) | CD274VSIRKCNT1PTPN1LMNA | |
| SCHEMBL18077936 | 0.86 | CD274 (0.58) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL19867093 | 0.86 | CD274 (0.58) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL18077944 | 0.81 | VSIR (0.61) | CD274VSIRPDCD1LG2PDCD1LMNA | |
| SCHEMBL19867037 | 0.81 | VSIR (0.61) | CD274VSIRPDCD1LG2PDCD1LMNA | |
| SCHEMBL19867090 | 0.79 | CD274 (0.61) | CD274VSIRPDCD1LG2PDCD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | PDCD1, CD274, PDCD1LG2 | CD274 2/4885VSIR 2158/4885KCNT1 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.